Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Year: 2024
Type: article
Authors: Valeria Santini, Rami S. Komrokji, Mikkael A. Sekeres, Michael Robert Savona, Pierre Fenaux, Yazan F. Madanat, Esther Oliva, Rena Buckstein, Anna Jonášová, Ulrich Germing, Moshe Mittelman, Sylvain Thepot, Jennifer Riggs, Souria Dougherty, Tymara Berry, Shyamala Navada, Qi Xia, Libo Sun, Amer M. Zeidan, Uwe Platzbecker
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4401896252